STTR Phase I: Steroid-eluting thread for the treatment of rhinitis

这项小型企业技术转移（STTR）一期项目具有更广泛的影响和商业潜力，是一种新颖的微创手术选择，可减少鼻炎患者的并发症并改善预后。一种生物可吸收、类固醇洗脱的缝合和手术植入程序将被开发出来，以改善600万名鼻炎患者在耳鼻喉科医生或耳鼻喉科专家的治疗下的预后。所建议的缝合系统和手术套装植入程序实现了一种临时治疗，取代了目前慢性、每日、局部喷雾剂和/或长期免疫治疗的需要，只需一次办公室就诊。生物可吸收的药物洗脱平台也为其他药物的洗脱提供了潜在的扩展性，包括抗生素和抗真菌治疗。这个小企业技术转移一期项目旨在提供一种类固醇洗脱可溶解线的原型，并引入一种手术工具。该项目由几个步骤组成，包括可溶解聚合物的配方，以及使用热熔挤出（HME）的原型。本研究为优化鼻腔用药物洗脱线的设计和开发提供了平台。该系统将使用首选类固醇糠酸莫米松设计，并在临床前动物模型中具有药物洗脱特性。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this this Small Business Technology Transfer (STTR) Phase I project is a novel, minimally invasive, surgical option for reducing complications and improving outcomes for rhinitis patients. A bioabsorbable, steroid-eluting suture and surgical implant procedure will be developed to improve outcomes for 6 million patients suffering from rhinitis under the care of otolaryngologists, or ear, nose and throat specialists. The proposed suture system and surgical suite implant procedure enables a temporary therapy that replaces the need for current chronic, daily, topical sprays and/or long-term immunotherapy with a single in-office visit. The bioabsorbable, drug-eluting platform also provides potential extensibility for eluting other medications including antibiotic and antifungal therapies. This Small Business Technology Transfer Phase I project aims to deliver a prototype steroid-eluting dissolvable thread with an introducing surgical tool. The project is comprised of several steps including the formulation of dissolvable polymers, and prototyping using Hot Melt Extrusion (HME). This effort will advance the platform design and development of optimized drug-elution thread for use in the nasal cavity. The system will be designed using the preferred steroid of mometasone furoate and characterized for drug elution properties in a preclinical animal model.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.